{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:04Z","timestamp":1753891864577,"version":"3.41.2"},"reference-count":7,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor an activating PIK3CA mutation. The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea. Herein, we report a case of a woman who developed diffuse depigmented macules on the face, arms and legs, three months after initiating alpelisib. Both clinical and histopathological findings were consistent with new-onset vitiligo. To our knowledge, this is the first case described in literature which suggests a causal relationship between alpelisib and irreversible dermatological adverse effect.<\/jats:p>","DOI":"10.3389\/fonc.2023.1255832","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:02:53Z","timestamp":1698663773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Maayan Geller","family":"Hinich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adham","family":"Hijab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.323","article-title":"New perspectives on the role of vitiligo in immune responses to melanoma","volume":"2","author":"Byrne","year":"2011","journal-title":"Oncotarget."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.65","article-title":"Melanocytes as instigators and victims of oxidative stress","volume":"134","author":"Denat","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B5","unstructured":"PI3K\/Akt-Nrf2 and anti-inflammation effect of macrolides in chronic obstructive pulmonary disease"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7591840","article-title":"Resveratrol attenuates oxidative stress-induced intestinal barrier injury through PI3K\/Akt-mediated Nrf2 signaling pathway","volume":"2019","author":"Zhuang","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/cdd.2015.117","article-title":"Oxidative stress-induced overexpression of miR-25: the mechanism underlying the degeneration of melanocytes in vitiligo","volume":"23","author":"Shi","year":"2016","journal-title":"Cell Death Differ"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1255832\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:02:56Z","timestamp":1698663776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1255832\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":7,"alternative-id":["10.3389\/fonc.2023.1255832"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1255832","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"article-number":"1255832"}}